Equillium (EQ) Competitors

Equillium (NASDAQ:EQ) and MacroGenics (NASDAQ:MGNX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership, media sentiment and risk.

Which has more risk and volatility, EQ or MGNX?

Equillium has a beta of 1.15, meaning that its share price is 15% more volatile than the S&P 500. Comparatively, MacroGenics has a beta of 1.65, meaning that its share price is 65% more volatile than the S&P 500.

Which has better valuation & earnings, EQ or MGNX?

Equillium has higher earnings, but lower revenue than MacroGenics. MacroGenics is trading at a lower price-to-earnings ratio than Equillium, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Equillium	$41.10M	0.43	-$8.07M	-$0.39	-1.27
MacroGenics	$152.43M	0.64	-$66.97M	-$0.89	-1.73

Does the media refer more to EQ or MGNX?

In the previous week, Equillium and Equillium both had 4 articles in the media. Equillium's average media sentiment score of 0.28 beat MacroGenics' score of 0.24 indicating that Equillium is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Equillium	0 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MacroGenics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do analysts recommend EQ or MGNX?

Equillium presently has a consensus target price of $3.00, suggesting a potential upside of 505.82%. MacroGenics has a consensus target price of $5.40, suggesting a potential upside of 250.65%. Given Equillium's higher probable upside, equities analysts plainly believe Equillium is more favorable than MacroGenics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Equillium	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33
MacroGenics	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.57

Is EQ or MGNX more profitable?

Equillium has a net margin of -19.62% compared to MacroGenics' net margin of -36.23%. MacroGenics' return on equity of -59.84% beat Equillium's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Equillium	-19.62%	-74.34%	-46.75%
MacroGenics	-36.23%	-59.84%	-23.45%

Do insiders & institutionals hold more shares of EQ or MGNX?

27.1% of Equillium shares are owned by institutional investors. Comparatively, 96.9% of MacroGenics shares are owned by institutional investors. 31.6% of Equillium shares are owned by insiders. Comparatively, 13.0% of MacroGenics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

MacroGenics beats Equillium on 9 of the 16 factors compared between the two stocks.